scholarly journals FIRST LIVE BIRTHS AFTER APPLICATION OF A READY-TO-USE IONOMYCIN IN CASES OF FAILED ARTIFICIAL OOCYTE ACTIVATION (AOA) USING CALCIMYCIN

2021 ◽  
Vol 116 (3) ◽  
pp. e199
Author(s):  
Thomas Ebner ◽  
Omar Shebl ◽  
Peter Oppelt
2015 ◽  
Vol 32 (3) ◽  
pp. 115-120
Author(s):  
Masahiro Sakurai ◽  
Shinichi Watanabe ◽  
Toyomi Tanaka ◽  
Rie Matsunaga ◽  
Naoko Yamanaka ◽  
...  

2019 ◽  
Vol 112 (3) ◽  
pp. e176
Author(s):  
Alberto Tejera ◽  
Lucia Alegre ◽  
Arantza Delgado ◽  
Jose Maria De los Santos ◽  
Jose Alejandro Remohi ◽  
...  

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Rui Long ◽  
Meng Wang ◽  
Qi Yu Yang ◽  
Shi Qiao Hu ◽  
Li Xia Zhu ◽  
...  

Abstract Background Whether artificial oocyte activation (ICSI-AOA) will increase the risk of birth defects remains controversial. Thus, we performed this study to evaluate the risk of birth defects and further compare the incidence of different birth defects types (chromosomal aberrations and non-chromosomal aberrations) in children conceived by ICSI-AOA and conventional intracytoplasmic sperm injection (ICSI) in an enlarged sample size. Method A comprehensive review of the literatures comparing birth defects in children conceived by ICSI-AOA and conventional ICSI by October 2020 was performed in PubMed, Embase, Cochrane Libraries, Web of Science, and Chinese databases including China National Knowledge Infrastructure, China Biology Medicine disc and Wan Fang. Risk ratios (RR) and 95% confidence intervals (CI) were calculated. Results Five studies were included in the final analysis. Compared with conventional ICSI, ICSI-AOA did not increase the birth defects rate (RR = 1.27, 95%CI 0.70–2.28) of children. Furthermore, in a subgroup analysis, birth defects were classified into two types (chromosomal aberrations and non-chromosomal aberrations) in four studies and no statistical difference were revealed. Conclusion Our analysis indicates that ICSI-AOA represents no significant difference in the prevalence of major birth defects or types of birth defects (chromosomal aberrations and non-chromosomal aberrations) comparing with conventional ICSI. This conclusion may provide clinicians evidence-based support in patient counseling and instruction of the application and safety concern about ICSI-AOA.


2018 ◽  
Vol 65 (1) ◽  
pp. 3-11 ◽  
Author(s):  
George Anifandis ◽  
Alexandros Michopoulos ◽  
Alexandros Daponte ◽  
Katerina Chatzimeletiou ◽  
Mara Simopoulou ◽  
...  

2015 ◽  
Vol 104 (3) ◽  
pp. e302
Author(s):  
A. Sdrigotti ◽  
G.J. Rey Valzacchi ◽  
F.A. Leocata Nieto ◽  
V.E. Canada

2013 ◽  
Vol 30 (12) ◽  
pp. 1569-1575 ◽  
Author(s):  
Hye Jin Yoon ◽  
In Hee Bae ◽  
Hyoung Jun Kim ◽  
Jung Mi Jang ◽  
Yong Su Hur ◽  
...  

Reproduction ◽  
2006 ◽  
Vol 131 (2) ◽  
pp. 259-267 ◽  
Author(s):  
Jean Loren ◽  
Orly Lacham-Kaplan

The present research investigated the effects of various strontium concentrations, in combination with different incubation periods, on mouse parthenogentic oocyte activation and blastocyst development. The results for blastocyst development showed a trend indicating that 10 mM strontium for 3 h was the optimal strontium protocol. Ethanol, an agent that incites oocyte activation via a monotonic rise in calcium, was employed as a control. The outcome of blastocyst formation arising from parthenogenic ethanol activation was significantly less (P < 0.001) than that achieved by the optimal strontium protocol. To assess the impact of strontium oocyte activation on embryo viability following fertilization with immature germ cells, the protocol of 10 mM strontium for 3 h was applied to oocytes injected with round spermatids and then compared with other protocols. The results indicate that following round-spermatid injection the benefits derived from strontium artificial oocyte activation are evident during both pre- and post-implantation development. However, in order to adjust the protocol to the most effective round-spermatid injection in relation to the oocyte cell cycle, injection was done 1.5 h after strontium activation followed by another 1.5 h activation in strontium. The implementation of round-spermatid injection in combination with this oocyte-activation protocol led to live-birth outcomes not significantly different to those outcomes obtained by mature spermatozoa.


Sign in / Sign up

Export Citation Format

Share Document